<DOC>
	<DOCNO>NCT01143246</DOCNO>
	<brief_summary>This study design evaluate efficacy safety intravenous Lucassin® ( terlipressin ) versus placebo treatment type 1 hepatorenal syndrome ( HRS ) subject receive standard care albumin therapy .</brief_summary>
	<brief_title>A Placebo-Controlled , Double-Blind Study Confirm Reversal Hepatorenal Syndrome Type 1 With Terlipressin</brief_title>
	<detailed_description>Hepatorenal syndrome rare syndrome mark renal dysfunction patient cirrhosis , decompensated liver disease , portal hypertension . Hepatorenal syndrome type 1 characterize rapid progressive renal impairment poor prognosis &gt; 80 % mortality within 3 month . At present , approved drug therapy HRS type 1 US , Australia , Canada . The curative treatment HRS type 1 underlying end-stage cirrhosis liver transplantation . However , many patient survive long enough receive liver transplant therapy , may provide bridge transplantation , badly need . Increased understanding pathophysiology HRS type 1 demonstrate vasoconstrictive drug therapy may reverse HRS type 1 . Substantial data available many publish clinical investigation literature provide compel evidence suggest administration terlipressin improve renal function patient HRS .</detailed_description>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>1 . Written inform consent subject legally authorize representative 2 . At least 18 year age 3 . Cirrhosis ascites 4 . Rapidly progressive reduction renal function characterize : SCr ≥ 2.5 mg/dL Doubling SCr within 2 week ( observation short duration , SCr value time meeting slopebased criterion proportional increase likely representative least double within 2 week 5 . No sustained improvement renal function ( &lt; 20 % decrease SCr SCr ≥ 2.25 mg/dL ) 48 hour diuretic withdrawal begin plasma volume expansion albumin : Note : Albumin dose recommend IAC 1 g/kg first day ( Maximum 100 g ) 20 40 g/day thereafter clinically indicated.It recommend ( clinically appropriate ) albumin dose kept constant study drug administration period . Note : The qualify SCr value SCr value least 48 hrs diuretic withdrawal ( applicable ) begin albumin fluid challenge . The qualify SCr value must ≥ 2.25 mg/dL AND least 80 % diagnostic ( prefluid challenge ) SCr value . 1 . Serum creatinine &gt; 7 mg/dL 2 . Shock Note : Hypotension ( Mean Arterial Pressure &lt; 70 mm Hg decrease &gt; 40 mm Hg systolic blood pressure baseline ) evidence hypoperfusion abnormality despite adequate fluid resuscitation . 3 . Sepsis systemic inflammatory response syndrome ( SIRS ) Note : SIRS : Presence 2 follow finding : Temperature &gt; 38°C &lt; 36°C ; heart rate &gt; 90/min ; respiratory rate &gt; 20/min PaCO2 &lt; 32 mm Hg ; white blood cell count &gt; 12,000 cells/µL &lt; 4,000/ µL . Note : Sepsis : Documented infection systemic inflammatory response syndrome . 4 . &lt; 2 day antiinfective therapy document suspected infection 5 . Proteinuria &gt; 500 mg/day 6 . Hematuria microhematuria ( &gt; 50 red blood cell per high power field ) 7 . Clinically significant cast urinalysis , include granular cast Note : Urine sediment examination require exclude presence granular cast clinically significant cast ( e.g. , red blood cell [ RBC ] cast ) . 8 . Evidence intrinsic parenchymal renal disease ( include acute tubular necrosis ) 9 . Obstructive uropathy renal pathology ultrasound medical image 10 . Current recent treatment ( within 4 week ) nephrotoxic drug , e.g. , aminoglycosides , nonsteroidal antiinflammatory drug ( NSAID ) Note : Up 3 dos NSAID within prior month ( prescription counter ) acceptable Note : Use shortterm ( &lt; 2 week ) oral neomycin acute encephalopathy acceptable . 11 . Current recent ( within 4 week ) renal replacement therapy 12 . Superimposed acute liver failure/injury due factor alcoholic hepatitis , include acute viral hepatitis , drug , medication ( e.g. , acetaminophen ) , toxin ( e.g. , mushroom [ Amanita ] poison ) 13 . Current recent treatment ( within 48 hour ) octreotide , midodrine , vasopressin , dopamine vasopressor 14 . Severe cardiovascular disease judge investigator 15 . Estimated life expectancy le 3 day 16 . Confirmed pregnancy 17 . Known allergy sensitivity terlipressin another component study treatment 18 . Participation clinical research study involve evaluation investigational drug device within 30 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatorenal syndrome</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Alcoholic hepatitis</keyword>
	<keyword>Ascites</keyword>
</DOC>